New agents and new formulations for the treatment of ovarian cancer

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 11, 2005, Pages 840-842

  Sabbatini, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACYLGLYCEROPHOSPHOCHOLINE ACYLTRANSFERASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; ENDOTHELIAL CELL GROWTH FACTOR; ERLOTINIB; GEFITINIB; HYB 2055; IMOXINE; OREGOVOMAB; PACLITAXEL; TAMOXIFEN; THALIDOMIDE; TRABECTEDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEMALE; HUMAN; INTESTINE PERFORATION; METABOLIC DISORDER; NOTE; OVARY CANCER; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; DIOXOLES; FEMALE; HUMANS; ISOQUINOLINES; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; QUINAZOLINES; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TETRAHYDROISOQUINOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 29744445130     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (9)

1. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955.
2. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.
3. Armstrong D, Bundy BN, Baergen R, et al. Randomized phase III study of intravenous paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecology Oncology Group trial (GOG 172). Proc Am Soc Clin Oncol. 2002;21. Abstract 21.
4. Burger R, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol. 2005;23. Abstract 5009.
5. Garcia AA, Oza AM, Fleming G, et al. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCtx) in recurrent and primary peritoneal carcinoma: A California Cancer consortium Trial. Am Soc Clin Oncol. 2005;23. Abstract 5000.
6. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11:5539-5548.
7. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;23:1867-1874.
8. Berek JS, Taylor PT, Gordon A, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol. 2004;22:3507-3516.
9. Springett GM, Bonham L, Hummer A, et al. Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res. 2005;65:9415-9425.